Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Leerink Swann increased their Q2 2017 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued on Monday. Leerink Swann analyst G. Porges now expects that the pharmaceutical company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.07. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Vertex Pharmaceuticals’ Q3 2017 earnings at $0.16 EPS, Q4 2017 earnings at $0.30 EPS and FY2017 earnings at $0.72 EPS.

VRTX has been the subject of several other research reports. Zacks Investment Research lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 10th. Maxim Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $143.00 price objective for the company in a research note on Friday, March 31st. Jefferies Group LLC initiated coverage on Vertex Pharmaceuticals in a research note on Monday, July 10th. They set a “buy” rating and a $155.00 price objective for the company. Barclays PLC reissued an “equal weight” rating and set a $100.00 price objective (up previously from $90.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, April 23rd. Finally, Vetr lowered Vertex Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $102.62 price objective for the company. in a research note on Tuesday, May 16th. Four analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $139.83.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/07/20/q2-2017-eps-estimates-for-vertex-pharmaceuticals-incorporated-nasdaqvrtx-boosted-by-leerink-swann.html.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 159.69 on Tuesday. Vertex Pharmaceuticals has a 52-week low of $71.46 and a 52-week high of $167.00. The stock has a 50 day moving average price of $129.31 and a 200 day moving average price of $106.81. The company has a market capitalization of $39.77 billion, a PE ratio of 222.72 and a beta of 1.74.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, April 27th. The pharmaceutical company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.09. Vertex Pharmaceuticals had a return on equity of 3.00% and a net margin of 8.64%. The company had revenue of $714.72 million during the quarter, compared to analysts’ expectations of $692.64 million. During the same period in the prior year, the business earned $0.09 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 79.5% compared to the same quarter last year.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 147,101 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $129.50, for a total transaction of $19,049,579.50. Following the sale, the chief executive officer now directly owns 312,142 shares of the company’s stock, valued at approximately $40,422,389. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey M. Leiden sold 157,200 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, April 28th. The shares were sold at an average price of $119.50, for a total value of $18,785,400.00. Following the sale, the chief executive officer now directly owns 395,152 shares in the company, valued at $47,220,664. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 404,670 shares of company stock worth $50,678,883. Insiders own 1.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Guardian Life Insurance Co. of America boosted its stake in Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the last quarter. Elk Creek Partners LLC boosted its stake in Vertex Pharmaceuticals by 0.3% in the first quarter. Elk Creek Partners LLC now owns 3,120 shares of the pharmaceutical company’s stock valued at $341,000 after buying an additional 10 shares during the last quarter. Sowell Financial Services LLC boosted its stake in Vertex Pharmaceuticals by 0.8% in the first quarter. Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company’s stock valued at $325,000 after buying an additional 23 shares during the last quarter. Capital Investment Advisory Services LLC boosted its stake in Vertex Pharmaceuticals by 0.4% in the first quarter. Capital Investment Advisory Services LLC now owns 6,463 shares of the pharmaceutical company’s stock valued at $707,000 after buying an additional 25 shares during the last quarter. Finally, First Manhattan Co. boosted its stake in Vertex Pharmaceuticals by 1.3% in the first quarter. First Manhattan Co. now owns 2,356 shares of the pharmaceutical company’s stock valued at $205,000 after buying an additional 31 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.